GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004
GlaxoSmithKline (GSK) is pleased to announce a call for applications for its 2004 Drug Discovery and Development Research Grant Program. GSK will award $250,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. Since the inception of the program in 2001, GSK has awarded $1.25 million and hono...Results of pivotal study for GlaxoSmithKline's Valtrex published in New England Journal of Medicine
Research Triangle Park, N.C., January 1, 2004 GlaxoSmithKline today announced the publication of results from a clinical trial evaluating VALTREX (valacyclovir HCl), an oral antiviral, in the reduction of transmission of genital herpes, in the Jan. 1 edition of the New England Journal of Medicine1. VALTREX significantly reduced the risk of transmitting herpes infection to a heterosexual partner...July 31 deadline approaching to apply for $500,000 in research grants from GlaxoSmithKline
GlaxoSmithKline (GSK) announced today a final call to submit applications for its Drug Discovery and Development Research Grant Program. Researchers working toward breakthroughs in HIV/AIDS drug therapies have until July 31, 2003, to apply. ...GSK will award $500,000 in research grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fi....San Diego, CA, September 27, 1998 - Clinical investigators today presented.Phase III clinical trial data for the HIV protease inhibitor Agenerase`.(amprenavir) which suggest that the drug may be potent and generally.well-tolerated in combination with Epivir" (lamivudine) also known as 3TC",.and Retrovir" (zidovudine; AZT). These data, presented at a late-breaker.slide session at the 38th Inter...